Stock quote - News

AstraZeneca
AZN: 6,089.00 +76.00 ( +1.26 %) delayed: 18:45PM


  • Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC
    Friday 24 May 2019 09:10

    Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and cut its price target to 6350p (from 6400p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
    Friday 24 May 2019 09:00

    Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7200p (from 7000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Friday 10 May 2019 08:10

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and cut its price target to 6800p (from 6900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 08 May 2019 17:00

    Marc Dunoyer, Financial Director, bought 8,500 shares in the company on the 7th May 2019 at a price of 5800.00p. The Director now holds 283,218 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca, Daiichi Sankyo breast cancer treatment meets primary goal
    Wednesday 08 May 2019 08:24

    AstraZeneca and Daiichi Sankyo Company said their breast cancer treatment had met its primary goal after demonstrating a 'clinically-meaningful response' in patients with a more aggressive version of the disease and poorer prognosis.  The response rate in DESTINY-Breast01, as assessed by an...
    Read more

  • UK stocks open 0.2% lower after new Trump tariff threat
    Tuesday 07 May 2019 08:48

    UK stocks opened lower on Tuesday after Donald Trump threatened to raise tariffs on Chinese goods, while a stronger pound put pressure on British companies with offshore sales. At 0842, the FTSE 100 was down 12.72 points, or 0.2%, at 7.367.92. Domino's Pizza sagged 6.8% after it said its...
    Read more

  • AstraZeneca's leukaemia treatment meets primary goal
    Tuesday 07 May 2019 07:51

    AstraZeneca said its treatment for chronic lymphocytic leukaemia had met its primary goal delivering an improvement in the time patients live without disease progression compared to an alternative combination treatment. Results from a clinical trial showed a statistically-significant and...
    Read more

  • AstraZeneca oral treatment for type-2 diabetes gets regulatory nod in US
    Friday 03 May 2019 08:05

    AstraZeneca said its oral treatment to aid type-2 diabetic patients to manage blood glucose levels had received regulatory approval from the US Food and Drug Administration. The US Food and Drug Administration (FDA) had approved Qternmet XR - a once-daily, oral medicine compromised of...
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Thursday 02 May 2019 16:25

    Philip Broadley, Non Executive Director, bought 520 shares in the company on the 30th April 2019 at a price of 5738.00p. The Director now holds 3,755 shares representing 0.00% of the shares in issue. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Thursday 02 May 2019 16:20

    Pascal Soriot, Chief Executive Officer, bought 17,100 shares in the company on the 29th April 2019 at a price of 5825.00p. The Director now holds 206,996 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Thursday 02 May 2019 10:50

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6900p (from 6800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 01 May 2019 15:00

    Philip Broadley, Non Executive Director, bought 520 shares in the company on the 30th April 2019 at a price of 5738.00p. The Director now holds 3,235 shares representing 0.00% of the shares in issue. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 01 May 2019 15:00

    Pascal Soriot, Chief Executive Officer, bought 17,100 shares in the company on the 30th April 2019 at a price of 5825.50p. The Director now holds 189,896 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Tuesday 30 Apr 2019 10:30

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and cut its price target to 6800p (from 6900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • FTSE back in the black by the close
    Monday 29 Apr 2019 16:46

    The FTSE 100 recovered its poise to trade 0.17% higher by the close at 7,440.66 with the US interest rate decision, trade talks and big corporate releases later this week all in focus. In the US, trading was off to a decent start with the parent of technology giant Google, Alphabet, poised to...
    Read more

  • FTSE's progress stalls as markets await Google-parent Alphabet's earnings
    Monday 29 Apr 2019 12:10

    The FTSE 100 surrendered earlier gains to trade 0.1% lower at 7,420.71 ahead of a busy week in terms of corporate and macro-economic news. In the US futures markets pointed to a positive start with the parent of technology giant Google, Alphabet, scheduled to report first quarter earnings....
    Read more

  • UK stocks nudge higher following positive US, China data
    Monday 29 Apr 2019 09:02

    UK stocks opened higher on Monday after positive US and Chinese economic data helped cool global growth fears. At 0853, the benchmark FTSE 100 index was up 11.79 points, or 0.2%, at 7.439.98. Miner and commodities trader Ferrexpo jumped 11% after it hit back against claims by its former auditor...
    Read more

  • AtraZeneca's ovarian cancer treatment receives positive opinion from European regulators
    Monday 29 Apr 2019 07:47

    AtraZeneca said European regulators had offered a positive opinion on it and partner MSD's treatment for ovarian cancer. The Committee for Medicinal Products for Human Use of the European Medicines Agency delivered a positive opinion on the cancer drug Lynparza and recommended it as a...
    Read more

  • AstraZeneca more than doubles profits in Q1 as newer cancer drugs boost growth
    Friday 26 Apr 2019 07:33

    AstraZeneca more than doubled pre-tax profits in the first quarter of the year as the continued success of its new medicines and emerging markets performance boosted product sales. For the 3 months to 31 March, pre-tax profits rose to $758m from $374m a year earlier as revenue rose 6% to...
    Read more

  • AstraZeneca, MSD advanced breast cancer treatment gets EU regulatory nod
    Wednesday 10 Apr 2019 07:14

    AstraZeneca and MSD said the European Commission had approved their drug to treat patients with advanced breast cancer. The approval was based on data from the phase III OlympiAD trial which tested Lynparza as a monotherapy for advanced/metastatic breast cancer - stage III and IV breast...
    Read more

  • Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLC
    Friday 05 Apr 2019 08:50

    Liberum Capital today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6400p (from 5800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 03 Apr 2019 11:25

    Marc Dunoyer, Financial Director, bought 4,838 shares in the company on the 29th March 2019 at a price of 0.00p. The Director now holds 274,718 shares. NOTE: Vesting - net of shares withheld to meet tax liabilities etc. Story provided by StockMarketWire.com Director deals data provided by...
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 03 Apr 2019 11:25

    Pascal Soriot, Chief Executive Officer, bought 15,755 shares in the company on the 29th March 2019 at a price of 0.00p. The Director now holds 172,796 shares. NOTE: Vesting - net of shares withheld to meet tax liabilities etc. Story provided by StockMarketWire.com Director deals data provided...
    Read more

  • Broker Forecast - HSBC issues a broker note on AstraZeneca PLC
    Tuesday 02 Apr 2019 11:20

    HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5180p (from 5140p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - UBS issues a broker note on AstraZeneca PLC
    Tuesday 02 Apr 2019 09:50

    UBS today downgrades its investment rating on AstraZeneca PLC (LON:AZN) to sell (from neutral) and cut its price target to 5400p (from 5900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
    Monday 01 Apr 2019 11:00

    Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7000p (from 6800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca, MSD neurofibromatosis type 1 drug gets breakthrough therapy designation in US
    Monday 01 Apr 2019 07:31

    AstraZeneca and MSD said their neurofibromatosis type 1 treatment had been granted breakthrough therapy designation from the US Food and Drug Administration. Mutations in the neurofibromatosis type 1, or NF1, gene may result in dysregulations in RAS/RAF/MEK/ERK signalling, which can cause...
    Read more

  • FTSE takes advantage of fall in sterling after May's Brexit deal defeated again
    Friday 29 Mar 2019 16:42

    The FTSE 100 continued to take advantage of a weaker pound after MPs rejected UK Prime Minister Theresa May's withdrawal agreement. By the close, the blue-chip index was up 0.6% at 7,279. Wall Street was a sea of green as investors were optimistic a resolution to the ongoing US-China trade war...
    Read more

  • FTSE higher as optimism over China-US trade talks builds
    Friday 29 Mar 2019 12:00

    The FTSE 100 traded up 0.4% by midday to 7,264.41 amid ongoing Brexit-related volatility in sterling and after gains in Asia overnight on hopes China is heading towards a resolution of its trade dispute with the US. US futures are pointing to a higher open when trading resumes on Wall Street...
    Read more

  • UK stocks open 0.5% higher as May readies Brexit deal for vote
    Friday 29 Mar 2019 08:54

    UK stocks opened higher on Friday amid renewed hope of progress in US-China trade talks and as Theresa May prepared to put a new version of her Brexit deal to another vote in parliament. At 0847, the FTSE 100 was up 35.57 points, or 0.5%, at 7.269.90. Travel company TUI slumped 10% after it...
    Read more

  • AstraZeneca to raise $3.5bn to support collaboration with Daiichi Sankyo on potential new cancer drug
    Friday 29 Mar 2019 08:06

    AstraZeneca said it would raised $3.5bn through the placing of shares to paydown debt and support its collaboration with Daiichi Sankyo Company to develop a potential new targeted medicine for cancer treatment. The placing price has yet to be announced. A total $1.35bn of the net proceed...
    Read more

  • Falling oil price hits FTSE 100
    Wednesday 27 Mar 2019 16:59

    Miners and oil majors weakened amid falling oil prices on reports US inventories rose last week, causing the FTSE 100 to dip 2.1 points to 7,194. Sterling was volatile throughout the day ahead of a series of indicative votes from MPs that could potentially result in a softer Brexit and after a...
    Read more

  • AstraZeneca's oral diabetes treatment gets regulatory nod in Japan
    Wednesday 27 Mar 2019 07:14

    AstraZeneca said Japanese regulators had approved its supplementary oral treatment for type-one diabetic patients, whose glucose levels were not adequately controlled with insulin alone. The approval was based on data from the Phase III DEPICT clinical programme diabetes treatment Forxiga...
    Read more

  • AstraZeneca's oral diabetes treatment gets European regulatory approval
    Monday 25 Mar 2019 07:23

    AstraZeneca said European regulators had approved its supplementary oral treatment for overweight type-one diabetic patients, whose glucose levels were not adequately controlled with insulin alone. 'The European Commission (EC) has approved Forxiga (dapagliflozin) for use in type-1 diabetes...
    Read more

  • FTSE gains as sterling weakens on potential Brexit setback
    Monday 18 Mar 2019 17:00

    Sterling fell sharply after House of Commons speaker John Bercow ruled out another vote on Theresa May's twice rejected Brexit deal if it is 'substantially the same.' The FTSE 100 moved higher on the weaker pound, rising 1% to 7,299. Ahead of a US Federal Reserve meeting this week, the Dow...
    Read more

  • UK stocks hold on to gains by midday as investors await big news
    Monday 18 Mar 2019 12:13

    With interest rate decisions on both sides of the Atlantic and further ructions on Brexit expected later this week, investors take advantage of a brief moment of calm as the FTSE 100 trades 0.6% higher at 7,271.09. In corporate news, payment processing firm WorldPay gained 10.3% to £81.70 as...
    Read more

  • Astrazeneca's lung disease treatment granted orphan drug status in US
    Monday 18 Mar 2019 07:42

    Astrazeneca said its potential new treatment for lung disease had been granted orphan drug designation by the US Food and Drug Administration. The company's 'potential' new medicine for the treatment of idiopathic pulmonary fibrosis (IPF), a type of lung disease that results in scarring...
    Read more

  • Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC
    Tuesday 12 Mar 2019 13:10

    Goldman Sachs today reaffirms its sell investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5000p (from 4080p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca, Merck breast cancer treatment gets EU regulatory nod
    Friday 01 Mar 2019 15:11

    AstraZeneca and Merck said they had a received a positive opinion from EU regulators on a treatment for breast cancer. The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the use of Lynparza tablets as monotherapy. The treatment was more specifically...
    Read more

  • AstraZeneca, Merck reveal positive results from pancreatic cancer treatment
    Tuesday 26 Feb 2019 08:58

    AstraZeneca and partner Merck revealed 'positive' results from the phase 3 clinical trial for their pancreatic cancer treatment, which met its primary objective. 'Results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival with...
    Read more

  • AstraZeneca heart treatment effective during trial
    Monday 25 Feb 2019 16:16

    AstraZeneca said a trial of a treatment for heart problems showed a reduction in major adverse cardiovascular events. The company's heart drug Themis taken together with Aspirin had shown a 'statistically-significant reduction in a composite of major adverse cardiovascular event compared to...
    Read more

  • Broker Forecast - Bryan Garnier issues a broker note on AstraZeneca PLC
    Friday 22 Feb 2019 10:50

    Bryan Garnier today downgrades its investment rating on AstraZeneca PLC (LON:AZN) to neutral (from neutral). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Pound weakens as another Brexit vote looms
    Thursday 14 Feb 2019 16:50

    The FTSE 100 was flat at 7,197 despite sterling falling on reports that the UK government could lose a Brexit-related parliamentary vote on Thursday evening. In the US, all stock markets slipped into the red on a shocking set of retail figures as sales fell 1.2%, way below analysts' expectations...
    Read more

  • Strong earnings and trade hopes push FTSE above 7,200
    Thursday 14 Feb 2019 12:13

    A mix of decent corporate results and hopes there will be progress in trade discussions between the US and China helped the FTSE 100 through the 7,200 mark by Thursday lunchtime. At midday the index of leading UK shares was up 0.4% to 7,217.62. European markets were also in positive territory...
    Read more

  • UK stocks edge higher ahead of fresh Brexit debates
    Thursday 14 Feb 2019 09:42

    UK stocks are climbing on Thursday morning with the market's attention on parliament's debates on Brexit expected latter in the session. At 08:58, the benchmark FTSE 100 was 0.39%, or 28.26 points, higher at 7,219.10. This is the first time since October that the index has risen above 7,200....
    Read more

  • AstraZeneca meets guidance as strong performance of new medicines deliver boost
    Thursday 14 Feb 2019 07:28

    AstraZeneca said Thursday a 'strong' fourth quarter led by performance of new medicines underscored its return to growth as the drugmaker met its guidance. For the 12 months to 31 December, revenue fell 2% to $22.1bn and product sales rose 4% to $21.05bn, which was in line with guidance for...
    Read more

  • FTSE 100 fails to gain momentum
    Wednesday 06 Feb 2019 17:05

    Global equities were pretty subdued with little news to drive any momentum, while the FTSE 100 was broadly unmoved at 7,173. Reports that European Council president Donald Tusk spoke of a 'special place in hell' for people who promoted Brexit without a plan failed to upset the pound. Wall...
    Read more

  • Weakness in utility stocks hits FTSE
    Wednesday 06 Feb 2019 12:11

    The FTSE 100 fell into negative territory as weakness in utilities and healthcare stocks dragged on performance. At midday, the blue-chip index was 0.1% lower at 7,166. MID AND LARGE RISERS AND FALLERS House builder Barratt Developments gained 2.8% after it unveiled a 19% rise in first-half...
    Read more

  • UK stocks open 0.3% lower as Brexit uncertainty weighs
    Wednesday 06 Feb 2019 09:01

    UK stocks opened lower on Wednesday as uncertainty over the course of Brexit negotiations and the state of US-China trade relations continued to weigh on investor sentiment. At 0852, the benchmark FTSE 100 was down 23.36 points, or 0.3%, at 7.154.01. House builder Barratt Developments gained...
    Read more

  • AstraZeneca treatment for hypereosinophilic syndrome granted orphan status
    Wednesday 06 Feb 2019 08:19

    AstraZeneca said US regulators had granted orphan drug status for its treatment for hypereosinophilic syndrome, a rare condition that can damage organs in the body. The Food and Drug Administration grants orphan status to medicines intended for the treatment of rare diseases or disorders that...
    Read more

Page 1 |

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.